newsfilter
← Latest News
Business Wire·

Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy

  • The FDA has approved Gazyva (obinutuzumab) for adult patients with primary membranous nephropathy (pMN) at risk of disease progression to induce remission of proteinuria.
  • This marks the first & only FDA approval for this disease, based on Phase III MAJESTY study results.
  • In the MAJESTY trial, Gazyva demonstrated superior efficacy over tacrolimus with 36.1% of patients achieving complete remission of proteinuria at two years compared to 5.7% for tacrolimus (p<0.001).
  • Gazyva also showed superiority in achieving overall remission (50% vs 12.9%) & complete remission at week 76 (36.1% vs 8.6%) compared to tacrolimus.
  • Safety data from the study aligned with Gazyva's known profile with no new safety signals identified.
  • pMN is a rare autoimmune disease that can lead to kidney failure in up to 30% of untreated patients within 10 years.
  • This approval is the third for Gazyva in immune-mediated kidney diseases following approvals for idiopathic nephrotic syndrome & lupus nephritis.
  • The FDA is currently evaluating Gazyva for systemic lupus erythematosus (SLE) with a decision expected by December 2026.
  • Serious safety risks associated with Gazyva include Hepatitis B reactivation, Progressive Multifocal Leukoencephalopathy (PML), infusion-related reactions, serious infections, neutropenia, thrombocytopenia, & Disseminated Intravascular Coagulation (DIC).
  • Gazyva is a humanized monoclonal antibody targeting CD20 on B cells to induce direct cell death & antibody-dependent cellular cytotoxicity.